Phibro Animal Health (NASDAQ:PAHC) CEO Sells $117,338.64 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 2,932 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $40.02, for a total transaction of $117,338.64. Following the transaction, the chief executive officer owned 44,525 shares in the company, valued at approximately $1,781,890.50. This trade represents a 6.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total transaction of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total value of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total value of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.77, for a total value of $143,510.40.
• On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $43.93, for a total value of $309,267.20.
• On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.02, for a total value of $232,425.60.

Phibro Animal Health Price Performance

Shares of NASDAQ PAHC opened at $41.07 on Friday. The stock has a fifty day moving average price of $40.59 and a 200 day moving average price of $37.10. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $46.42. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35. The company has a market cap of $1.66 billion, a PE ratio of 24.74, a P/E/G ratio of 1.16 and a beta of 0.79.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. The company had revenue of $363.89 million during the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Sell-side analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th were given a $0.12 dividend. The ex-dividend date was Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 28.92%.

Institutional Investors Weigh In On Phibro Animal Health

Institutional investors and hedge funds have recently modified their holdings of the company. Financial Management Professionals Inc. acquired a new position in Phibro Animal Health during the second quarter worth $32,000. Hughes Financial Services LLC acquired a new stake in Phibro Animal Health in the third quarter valued at $40,000. iSAM Funds UK Ltd purchased a new position in shares of Phibro Animal Health in the third quarter valued at $61,000. EverSource Wealth Advisors LLC raised its stake in shares of Phibro Animal Health by 7,671.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after buying an additional 2,685 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new position in shares of Phibro Animal Health during the 3rd quarter worth $96,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on PAHC shares. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. JPMorgan Chase & Co. upped their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Phibro Animal Health presently has a consensus rating of “Hold” and an average price target of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.